Table 1.
Patient characteristics in the studies included in the analysis.
| Study, first author, year | Blinding | Follow up (weeks) | Sizes | Outcomes | Intervention | Cases | Female | Disease durations (year) | Age (year) |
|---|---|---|---|---|---|---|---|---|---|
| Swefot (TBD), van Vollenhoven et al., 2009 | Open-label | 52 | 258 | ①③④ | cDMARDs | 130 | 101 | 0.525 (0.3) | 53.9 (13.9) |
| IFX+MTX | 128 | 97 | 0.517 (0.29) | 51.1 (13.3) | |||||
| Nishimoto, 2004, Nishimoto et al., 2004 | Double-blind | 12 | 162 | ①③ | PBO | 53 | 39 | 8.4 | 53 |
| TCZ | 54 | 40 | 7.3 | 53.5 | |||||
| TCZ | 55 | 46 | 8.3 | 56 | |||||
| GUEPARD, Soubrier et al., 2009 | Unblinded | 52 | 65 | ①② | cDMARDs | 32 | 26 | 4.4 | 49.3 (15.2) |
| ADA+MTX | 33 | 26 | 4.4 | 46.3 (16.3) | |||||
| ASPIRE, St Clair et al., 2004 | Not specified | 46 | 1,004 | ①②③④ | cDMARDs | 282 | 212 | 0.9 (0.7) | 50 (13) |
| IFX+MTX | 359 | 255 | 0.8 (0.7) | 51 (12) | |||||
| IFX+MTX | 363 | 247 | 0.9 (0.8) | 50 (130) | |||||
| OPTIMA, Kavanaugh et al., 2013 | Double-blind | 26 | 1,032 | ①②③④ | ADA+MTX | 515 | 380 | 0.33 (0.3) | 50.7 (14.5) |
| cDMARDs | 517 | 382 | 0.375 (0.6) | 50.4 (13.6) | |||||
| BeST, Goekoop-Ruiterman et al., 2008 | Double-blind | 26 | 254 | ①③④ | cDMARDs | 126 | 86 | 0.44 | 54 (13) |
| IFX+MTX | 128 | 85 | 0.62 | 54 (14) | |||||
| GO-BEFORE, Emery et al., 2009 | Double-blind | 24 | 637 | ①②③④ | cDMARDs | 160 | 134 | 2.9 (4.80) | 48.6 (12.91) |
| GOL | 159 | 134 | 4.1 (5.60) | 48.2 (12.85) | |||||
| GOL+MTX | 159 | 135 | 3.5 (5.65) | 50.9 (11.32) | |||||
| GOL+MTX | 159 | 125 | 3.6 (6.09) | 50.2 (11.87) | |||||
| COMET, Emery et al., 2008a | Double-blind | 104 | 528 | ①②③④ | cDMARDs | 263 | 191 | 0.78 (0.03) | 52.3 (0.8) |
| ETN+MTX | 265 | 196 | 0.73 (0.03) | 50.5 (0.9) | |||||
| Durez2007, Durez et al., 2007 | Double-blind | 52 | 29 | ① | cDMARDs | 14 | 10 | 0.45 (0.29) | 53.8 (15.2) |
| IFX+MTX | 15 | 5 | 0.36 (0.31) | 50.0 (9.9) | |||||
| PREMIER, Breedveld et al., 2006 | Double-blind | 104 | 799 | ①② | ADA+MTX | 268 | 193 | 0.7 (0.8) | 51.9 (14.0) |
| ADA | 274 | 212 | 0.7 (0.8) | 52.1 (13.5) | |||||
| cDMARDs | 257 | 190 | 0.8 (0.9) | 52.0 (13.1) | |||||
| Bathon, 2000, Bathon et al., 2000 | Double-blind | 52 | 632 | ①③ | cDMARDs | 217 | 163 | 1 (0.92) | 49 (13) |
| ETN | 208 | 156 | 0.92 (0.83) | 50 (13) | |||||
| ETN | 207 | 153 | 1 (0.92) | 51 (13) | |||||
| Bejarano, 2008, Bejarano et al., 2008 | Double-blind | 56 | 128 | ①②③④ | cDMARDs | 73 | 39 | 0.66 (0.45) | 47 (9) |
| ADA+MTX | 75 | 44 | 0.79 (0.5) | 47 (9) | |||||
| HITHARD, Detert et al., 2013 | Double-blind | 48 | 172 | ①②④ | ADA+MTX | 87 | 61 | 0.15 (0.17) | 47.2 (12.12) |
| cDMARDs | 85 | 57 | 0.13 (0.14) | 52.5 (14.34) | |||||
| Quinn, 2005, Quinn et al., 2005 | Double-blind | 52 | 20 | ①② | IFX+MTX | 10 | N/A | 0.62 (0.38) | 51.3 (9.5) |
| cDMARDs | 10 | N/A | 0.5 (0.31) | 53.1 (13.7) | |||||
| OPERA, Hørslev-Petersen et al., 2014 | Double-blind | 52 | 180 | ①④ | ADA+MTX | 89 | 56 | 88 days | 56.2 |
| cDMARDs | 91 | 63 | 83 days | 54.2 | |||||
| C-EARLY, Emery et al., 2016 | Double-blind | 52 | 868 | ①②③④ | cDMARDs | 213 | 170 | 0.24 (0.24) | 51.2 (13.0) |
| CZP+MTX | 655 | 497 | 0.24 (0.38) | 50.4 (13.6) | |||||
| U-Act-Early, Bijlsma et al., 2016 | Double-blind | 24 | 317 | ①③④ | TCZ+MTX | 106 | 65 | 24.5 days | 53 |
| TCZ | 103 | 78 | 25.5 days | 55 | |||||
| cDMARDs | 108 | 69 | 27.0 days | 53.5 | |||||
| Function, Burmester et al., 2013 | Double-blind | 52 | 1,157 | ①②③④ | cDMARDs | 287 | 229 | 0.4 (0.48) | 49.6 (13.1) |
| TCZ+MTX | 288 | 228 | 0.4 (0.49) | 51.2 (13.84) | |||||
| TCZ+MTX | 290 | 228 | 0.5 (0.53) | 49.5 (13.70) | |||||
| TCZ | 292 | 219 | 0.5 (0.48) | 49.9 (13.22) | |||||
| C-OPERA, Atsumi et al., 2015 | Double-blind | 24 | 316 | ②③④ | cDMARDs | 157 | 127 | N/A | 49 (10.3) |
| CZP+MTX | 159 | 129 | N/A | 49.4 (10.6) | |||||
| RADIATE, Emery et al., 2008b | Double-blind | 24 | 489 | ①②③④ | TCZ+MTX | 170 | 84 | 12.6 (9.3) | 53.9 (12.7) |
| TCZ+MTX | 161 | 81 | 11.0 (8.5) | 50.9 (12.5) | |||||
| cDMARDs | 158 | 79 | 11.4 (9.2) | 53.4 (13.3) |
① ACR.
② Remission.
③ adverse effects (AEs).
④ serious adverse effects.
cDMARDs: conventional disease-modifying antirheumatic drugs; MTX: methotrexate; ADA: adalimumab; CZP: certolizumab; ETN: etanercept; GOL: golimumab; IFX: infliximab; TCZ: PBO: tocilizumab; placebo.